GlassScriptPhysician profile
Keith W Lackey
NPI 1154389815
$6,369.02
in general payments reported to CMS, 2019-2025
53 companies · $1,072 in 2025
The $1,072 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $510 · 2020: $619 · 2021: $1,129 · 2022: $1,076 · 2023: $1,082 · 2024: $881 · 2025: $1,072.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,035.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,034.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $566.55 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $499.17 | 2019-2025 | Evenity, Repatha, Prolia |
| Abbvie INC. | $444.40 | 2020-2025 | |
| Pfizer INC. | $385.11 | 2021-2025 | |
| Novo Nordisk INC | $381.23 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $339.43 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Exact Sciences Corporation | $336.91 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $315.67 | 2019-2025 | Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $266.97 | 2019-2024 | Xifaxan |
| Astellas Pharma US INC | $202.77 | 2021-2023 | Myrbetriq, Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $201.29 | 2021-2025 | |
| Abbott Laboratories | $178.71 | 2021-2025 | Eterna, Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $156.69 | 2023-2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.39 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $143.00 | 2022-2023 | Qelbree |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Lackey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.